These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 3518753

  • 1. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
    Rosenberg SA, Lotze MT.
    Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
    [No Abstract] [Full Text] [Related]

  • 2. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
    [No Abstract] [Full Text] [Related]

  • 3. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA.
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [Abstract] [Full Text] [Related]

  • 4. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
    Sondel PM, Hank JA, Kohler PC, Chen BP, Sosman J.
    Prog Clin Biol Res; 1989 Oct; 288():151-60. PubMed ID: 2654949
    [No Abstract] [Full Text] [Related]

  • 5. Natural killer cells and tumor immunity: 1987.
    Hiserodt JC, Herberman RB.
    Year Immunol; 1989 Oct; 4():201-7. PubMed ID: 2648702
    [No Abstract] [Full Text] [Related]

  • 6. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
    Rosenberg S.
    J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
    [No Abstract] [Full Text] [Related]

  • 7. Immunotherapy of cancer: the end of the beginning?
    Durant JR.
    N Engl J Med; 1987 Apr 09; 316(15):939-41. PubMed ID: 3493434
    [No Abstract] [Full Text] [Related]

  • 8. In vivo kinetics of murine lymphoid cells: in relation to local adoptive cancer immunotherapy.
    Yamasaki N, Kan N, Inamoto T, Nakayama N, Nio Y, Hori T.
    Nihon Geka Hokan; 1984 Jan 01; 53(1):67-78. PubMed ID: 6333856
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
    Rosenberg SA.
    Ann Surg; 1988 Aug 01; 208(2):121-35. PubMed ID: 3041925
    [Abstract] [Full Text] [Related]

  • 17. Summary: potential of interleukin-2 for the therapy of cancer.
    Herberman RB.
    J Biol Response Mod; 1984 Oct 01; 3(5):527-32. PubMed ID: 6389778
    [No Abstract] [Full Text] [Related]

  • 18. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 01; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 19. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA.
    Important Adv Oncol; 1986 Jun 01; ():55-91. PubMed ID: 3330541
    [No Abstract] [Full Text] [Related]

  • 20. Development of new immunologic approaches to cancer therapy.
    Rosenberg SA.
    Blood Purif; 1988 Jun 01; 6(2):69-76. PubMed ID: 3293619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.